© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
GRAIL Inc. (GRAL) stock surged +3.46%, trading at $72.70 on NASDAQ, up from the previous close of $70.27. The stock opened at $70.63, fluctuating between $69.46 and $73.00 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 04, 2026 | 71.23 | 73.00 | 69.17 | 72.70 | 532.44K |
| Aug 03, 2026 | 69.53 | 71.51 | 66.65 | 70.27 | 365.85K |
| Jul 31, 2026 | 71.50 | 71.57 | 67.16 | 68.56 | 560.33K |
| Jul 30, 2026 | 65.05 | 71.45 | 64.32 | 71.14 | 546.4K |
| Jul 29, 2026 | 63.55 | 65.88 | 62.09 | 63.44 | 518.45K |
| Jul 28, 2026 | 66.06 | 66.80 | 63.26 | 64.42 | 789.35K |
| Jul 27, 2026 | 69.66 | 69.66 | 66.15 | 66.77 | 441.41K |
| Jul 24, 2026 | 72.11 | 72.11 | 67.47 | 67.84 | 350.42K |
| Jul 23, 2026 | 69.89 | 72.70 | 69.74 | 70.36 | 646.69K |
| Jul 22, 2026 | 72.84 | 73.05 | 70.14 | 70.66 | 321.96K |
| Jul 21, 2026 | 68.84 | 73.53 | 68.11 | 72.71 | 482.57K |
| Jul 20, 2026 | 72.35 | 72.57 | 68.64 | 68.91 | 449.76K |
| Jul 17, 2026 | 70.00 | 72.75 | 69.69 | 72.62 | 413.75K |
| Jul 16, 2026 | 73.94 | 75.16 | 69.83 | 71.96 | 429.91K |
| Jul 15, 2026 | 72.67 | 75.00 | 72.56 | 74.36 | 540.08K |
| Jul 14, 2026 | 72.89 | 74.58 | 71.06 | 73.12 | 386.03K |
| Jul 13, 2026 | 69.98 | 73.13 | 69.45 | 71.80 | 365.15K |
| Jul 10, 2026 | 75.81 | 76.07 | 69.75 | 72.00 | 509.3K |
| Jul 09, 2026 | 70.30 | 76.00 | 70.19 | 75.79 | 730.22K |
| Jul 08, 2026 | 66.21 | 70.43 | 66.00 | 70.14 | 834.48K |
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
| Employees | 910 |
| Beta | 3.22 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |